55,000 Shares in Qiagen (NYSE:QGEN) Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new stake in Qiagen (NYSE:QGEN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 55,000 shares of the company’s stock, valued at approximately $2,389,000.

Other large investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new stake in Qiagen during the third quarter worth approximately $31,000. Toronto Dominion Bank acquired a new position in Qiagen in the third quarter valued at about $41,000. Lindbrook Capital LLC lifted its position in Qiagen by 21.6% during the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after purchasing an additional 237 shares during the period. Blue Trust Inc. grew its stake in Qiagen by 253.9% during the fourth quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock worth $161,000 after buying an additional 2,851 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in Qiagen by 9.0% in the 3rd quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock valued at $190,000 after buying an additional 385 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.1 %

Shares of QGEN traded up $0.03 on Tuesday, reaching $42.33. The company’s stock had a trading volume of 2,113,233 shares, compared to its average volume of 1,220,508. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.70. The stock has a market capitalization of $9.66 billion, a PE ratio of 27.98, a PEG ratio of 3.51 and a beta of 0.41. The company has a current ratio of 1.99, a quick ratio of 1.62 and a debt-to-equity ratio of 0.24. The firm has a fifty day moving average of $42.57 and a 200-day moving average of $42.69.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a net margin of 17.37% and a return on equity of 12.99%. The firm had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same quarter in the prior year, the business posted $0.53 EPS. The business’s revenue was down 5.4% compared to the same quarter last year. Equities analysts predict that Qiagen will post 2.09 EPS for the current year.

Analyst Ratings Changes

QGEN has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, February 8th. Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $49.48 to $51.00 in a report on Friday, February 16th. Finally, Citigroup reduced their price objective on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.69.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.